Skip to main content

11 November 2025

Last updated: Monday 10 November 2025

User account anon menu

Login
Register and subscribe

Search

Home
News
About MedNous
Research Directory
Contact Us
- Contact Form

Menu

Breadcrumb

Home
Research Directory

Research Directory

Developing radionuclide PARP inhibitors

Sunday 22 November 2020

Interviewee/Contributor

Greg Mullen

Organisation

Theragnostics Ltd

Organisations

European Commission
ImmunOs Therapeutics AG
University of Medicine and Dentistry of New Jersey
Forendo Pharma Ltd
Purespring Therapeutics Ltd
Takeda Ventures
IBA Molecular
RXi Pharmaceuticals Corp
Ark Therapeutics Plc
ISA Pharmaceuticals BV

Interviewees and Contributers

Niall Martin and Jonathan Tobin
Don Picker
Alex Karlsson-Parra and Sijme Zeilemaker
Gregg Sando
Pierre Belichard
Peter Charlish
Iain Wilcock
Priya Kalia and Miranda Weston-Smith
Graeme Martin
Ulrich Mahr

Select a News Category

Clinical Research
Company News
Finance, Grants, Deals
IPR & Legal
Regenerative Medicine
Regulation & Policy
Research & University News

Recent Appointments

Werner Lanthaler appointed CEO of FairJourney Biologics

Thursday 6 November 2025

New CEO at Evaxion

Thursday 6 November 2025

Draig Therapeutics appoints President and CEO

Thursday 6 November 2025

Forbion appoints partner in growth fund

Thursday 6 November 2025

Amphista Therapeutics names executives to drive clinical development

Thursday 6 November 2025

View more appointments

Looking for more?

MedNous covers medical news and more. See more in our various site sections.

News
Industry appointments
Events
Research directory
Subscribe

Footer

Privacy policy

© 2025 Evernow Publishing Ltd.

Home
News
- News
- Appointments
- Events
About MedNous
Research Directory
Contact Us
- Contact Form